GOTHENBURG, Sweden, 13 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) carried out a rights issue of units […]
GOTHENBURG, Sweden, 11 March 2026 – Isofol Medical AB (“Isofol” or the “Company”) announces today that the Company has received
GOTHENBURG, Sweden, March 9, 2026 – The Nomination Committee of Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) proposes re-election of
GOTHENBURG, Sweden, March 3, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate
GOTHENBURG, Sweden, February 24, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) today provides an update on the company’s
GOTHENBURG, Sweden, February 18, 2026 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
GOTHENBURG, Sweden, January 9, 2026 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces today that the company will participate
GOTHENBURG, Sweden, December 1, 2025 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL) announces that the company will participate in
GOTHENBURG, Sweden, November 13 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the European Patent Office
GOTHENBURG, Sweden, November 12, 2025 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), (”Isofol” or the ”Company”), announced today that
